All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
A Phase 2 Study of Lisocabragene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Agressive B-Cell NHL (017006)
Phase 1, Open Label, Multicenter, Dose Escalation Study of YTB323 in Adult Patients with CLL/SLL and DLBCL
A Pilot Study of Zydelig in Patients with B-Cell Malignancies as Post-Autologous Transplant Remission Maintenance
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma.
A Phase I Study of Neihulizumab (AbGn-168H) in Patients with Steroid-refractory Acute Graft-Versus-Host Disease (sr-aGvHD)
Alliance-A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with CLL
Alliance A041501: A phase III trial to evaluate the efficacy of the addition of inotuzumab ozogamicin (a conjugated anti-CD22 monoclonal antibody) to front-line therapy in young adults (ages 18-39 years) with newly diagnosed precursor B-cell ALL
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in CML Patients with Molecular Evidence of Disease
Alliance A041703: A phase II study of inotuzumab ozogamicin followed by blinatumomab for Ph-negative, CD22-positive B-lineage ALL in newly diagnosed older adults or adults with relapsed or refractory disease
Phase 2 Trial of Intensive Chemo-immunotherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the Context of Salvage Autologous Hematopoietic Cell Transplantation
A Phase 1B/2 Study to Evaluate the safety, Tolerability, Phamacokinetics, Phamacodynamics, and Clinical Activity or EQ001 In Subjects with Newly Diagnosed Acute Graft Versus Host Disease
This is a phase I trial. The purpose of the study is to observe the safety, efficacy (good or bad) and determine the maximum dose of Lintuzumab-Ac225 that can be given to patients with multiple myeloma like you without causing bad effects.